Good sales trend focusing on Europe and North America
* Net sales for the period were SEK 34.1 million (27.7), an
increase of 23 per cent, of which SEK 17.3 million (18.6) in the
second quarter.
* The operating loss for the period was SEK -3.7 million (-5.0)
and for the second quarter SEK -2.8 million (-0.3).
* Earnings per share for the period were SEK -0.17 (-0.22).
* Cash and cash equivalents amounted to SEK 8.8 million at the end
of the period.
* The company was listed on First North on 28 May.
* A new subsidiary was established in Canada.
* Four systems were installed at the Karolinska University
Laboratory.
Significant events after the close of the reporting period
* There was a preview of the new application for body fluids in
the USA in July.
* Johan Wennerholm was employed as Chief Financial Officer.
CellaVision in summary
1 jan-30 june 1 jan-30 june Full year
(SEK m) 2007 2006 2006
Net sales 34.1 27.7 54.8
Gross profit 19.8 15.4 32.0
Operating loss -3.7 -5.0 -8.6
Net profit -3.9 -5.2 -8.8
Cash flow -8.0 -0.3 -0.8
CEO's comments"Up to and including the second quarter CellaVision has delivered a
total of 300 systems to customers, mainly in Europe and North
America. The initiative in Canada with our own company has attracted
great attention to our products, and the number of identified
potential customers exceeds expectations. The new body fluid analysis
application also generated great interest when it was shown at the
international AACC Annual Meeting and Clinical Lab Expo in San Diego,
USA in July," says Yvonne Mårtensson, CEO of CellaVision AB."The company's listing on First North has been completed and was well
received. With continued good growth I look forward with confidence
to achieving profitability in our core business - the hematology
market."
Yvonne Mårtensson
CEO CellaVision AB
For more information, please contact:
Yvonne Mårtensson, CEO. Phone: 0708 33 77 82, e-mail:
yvonne.martensson@cellavision.se
Johan Wennerholm, CFO. Phone: 0708 33 81 68, e-mail:
johan.wennerholm@cellavision.se
